Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.
Meningiomas are relatively common (22%) vascular brain tumors. 3-11% of meningiomas are malignant, and defy currently available therapy. Inhibition of neovascularization is one potential strategy for treating these hypervascular tumors. Inhibition of tumor-induced angiogenesis by TNP-470 (previously termed AGM-1470), a synthetic analogue of fumagillin, was tested on the growth of human non-malignant and malignant meningiomas in nude mice. TNP-470 significantly inhibited tumor neovascularization and tumor growth of both non-malignant and malignant meningiomas. TNP-470 is now in human trial and should be tested for efficacy in treating malignant or recurrent aggressive meningiomas.
Yazaki
T
T
Georgetown Brain Tumor Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Takamiya
Y
Y
Costello
P C
PC
Mineta
T
T
Menon
A G
AG
Rabkin
S D
SD
Martuza
R L
RL
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D017690:Cell Transplantation; D003510:Cyclohexanes; D005260:Female; D006801:Humans; D008577:Meningeal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D008579:Meningioma / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D017253:Neurofibromatoses / Q000188:drug therapy; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012039:Regional Blood Flow / Q000187:drug effects; D012717:Sesquiterpenes / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000077609:O-(Chloroacetylcarbamoyl)fumagillol